logo
Clicks! Likes! Sugar! Gambling! In a world of quick pleasures, an addiction expert says it might be time for a ‘dopamine fast'

Clicks! Likes! Sugar! Gambling! In a world of quick pleasures, an addiction expert says it might be time for a ‘dopamine fast'

CNN9 hours ago
FacebookTweetLink Maybe you'd like to spend time on hobbies or hang out with friends, but nothing feels as exciting and engaging as it used to –– so you just squander another hour on social media.
Your problem may have to do with your dopamine levels.
In many parts of the world, people are fed media, activities and foods that can cause dopamine to surge and throw the balance off, and that could affect your mental health, according to Dr. Anna Lembke, professor of psychiatry and behavioral sciences at Stanford University School of Medicine, chief of the Stanford Addiction Medicine Dual Diagnosis Clinic and author of 'Dopamine Nation: Finding Balance in the Age of Indulgence.'
Lembke spoke with CNN about what dopamine is, what it does and how you can find better balance.
This conversation has been lightly edited and condensed for clarity.
CNN: What is dopamine exactly?
Dr. Anna Lembke: Dopamine is a chemical we make in our brain. Specifically, it's a neurotransmitter. Neurotransmitters allow for fine-tuned regulation of electrical circuits. Basically, our brain is a bunch of electrical circuits, a bunch of wires in the form of neurons that conduct electrical signals that allow for information processing — the job of our brains.
Dopamine has many functions, but in the last 75 years or so, it's been identified as a key player in pleasure, reward and motivation. It's not the only neurotransmitter involved in that process, but it has become a kind of common currency for neuroscientists to measure the reinforcing potential of different substances and behaviors.
CNN: How does dopamine impact our mental health?
Lembke: It plays a central role in the phenomenology of addiction. Addiction is a brain disease where there's dysregulation in a specific reward pathway, a specific circuit in the brain, and dopamine plays a critical role in the brain's reward pathway.
When we do something that's reinforcing, that releases dopamine in the reward pathway and tells our brain, 'Oh, that's something you need to do more of. That's important for survival.'
The highly reinforcing substances and behaviors that we have engineered and have access to now are overwhelming the system. (They) release so much dopamine all at once in the reward pathway that the brain has to adapt or compensate by downregulating dopamine transmission.
The result is that, over time, we can enter into a chronic dopamine-deficit state, where we have essentially changed our hedonic or joy set point. Now we need more of our reward — and more potent forms –– not to feel good, but just to stop feeling bad. And when we're not 'using,' we're experiencing the universal symptoms of withdrawal from any addictive substance or behavior like anxiety, irritability, insomnia, dysphoria and craving.
CNN: Does this just affect people who have an addiction to drugs or alcohol?
Lembke: We're all now kind of on the spectrum of compulsive overconsumption, moving toward addiction, which is resetting our hedonic threshold –– or joy set point. We need more and more of these reinforcers to feel any pleasure at all, and when we're not using, we're dysphoric, we're irritable, we can't sleep.
CNN: What kinds of things risk putting us into dopamine deficit?
Lembke: A lot of different things release dopamine in the reward pathway, including things that are good for us, like learning or spending time with friends.
It's not that dopamine is the villain here, that dopamine release is bad –– not at all. The problem is that we've now engineered old-fashioned drugs to be more potent than ever before, and we've also created drugs that never existed before, like digital media, like 'drugified' foods. We've even taken healthy behaviors like exercise and drugified them by (tracking) ourselves and ranking ourselves and adding in social media and social comparisons.
We're now seeing more and more and more people addicted to social media, online pornography, online gambling, video games and all manner of addictive digital media. There's emerging evidence that these digital media activate the same reward pathways as drugs and alcohol and cause the same kinds of dysregulations as we see in other addictions.
It's the same thing with sugar. Ultraprocessed foods cause dopamine release, and the reward pathway leads to the same kinds of behaviors as when people get addicted to drugs and alcohol. There's a growing consensus that it's basically the same disease process, just with a different object of desire or reward.
CNN: How can we find out if a substance or behavior is problematic?
Lembke: When we look at what makes something addictive, there are several factors. One is potency, which refers to how much dopamine is released in the reward pathway and how quickly it's released. But other factors are simple things like access.
We know that the easier it is to access a reinforcing substance or behavior, the more likely people are to use it and hence get addicted to it. We now live in this world of very easy, frictionless access to a lot of rewarding substances and behaviors.
Digital media in particular is a 24/7 mobile access — anytime, anywhere, to an almost infinite source.
The other thing that makes something addictive is the quantity and frequency of exposure. The more dopamine hits the brain gets, the more likely it is to change and adapt in a way that can create a disease of addiction. (Social media algorithms are) actually engineered to overcome tolerance and create novelty, to encourage people to keep searching for the same or similar rewards as what they've already viewed but hopefully a little bit better.
The criteria for diagnosing addiction are pretty much the same across different definitions. You're looking for the four C's: out-of-control use, compulsive use, craving and consequences — especially continued use despite consequences — as well as the physiologic criteria that indicate biological dependence. Those would be tolerance, needing more (or more potent forms) over time to get the same effect, and withdrawal when you try to stop using.
CNN: What can we do to address dopamine deficit?
Lembke: What I recommend is a 30-day abstinence trial, colloquially called a 'dopamine fast,' from the drug of choice. Not from all rewards but just from the problematic substance or behavior to see how difficult it is to stop — and also to see if you feel better after four weeks.
Why four weeks? Because that's, on average, the amount of time it takes to reset reward pathways, at least phenomenologically. I always warn people, they're going to feel worse before they feel better. But if they get through the first 10 to 14 days, often they will feel much better.
After the abstinence trial, when people want to go back to using, they just need to be very specific about what they're going to use, how much, how often, in what circumstances, how they're going to track it, and what their red flags will be for slipping back into old habits.
Then they can reevaluate whether they can really use in moderation. When it comes to food, obviously, people can't abstain, and nor should they try. But they can abstain from sugar. They can abstain from ultraprocessed foods.
How do we engage in pleasurable things but stop before we get to dopamine deficit?
Lembke: It's not about not having pleasure in life; it is about resetting the balance so that simple pleasures are rewarding again. That is not going to happen if people are constantly indulging in these frictionless, high-potency rewards.
I talk a lot about 'self-binding' and making sure we don't constantly surround ourselves with easy access to these high-potency, cheap pleasures so we don't get into that problem in the first place.
But it takes intentionality because we live in a world where we're constantly being invited to consume, and we're told that the more we consume, the happier we'll be. So, it does take planning and intentionality to create barriers between ourselves and the many drugs out there.
Self-binding can mean physical barriers. If the issue is food, not having ultraprocessed food or sugary food in the house. If it's cannabis, not having pot in the house, not having alcohol. Now, if it's some form of digital media, you can use time as a self-binding strategy: 'I'm only going to use on these days for this amount of time with these people.'
Other people are a very important form of self-binding. We tend to do what those around us are doing, so try to hang out with people who are using substances and behaviors in a way that you want to use them.
Sign up for CNN's Stress, But Less newsletter. Our six-part mindfulness guide will inform and inspire you to reduce stress while learning how to harness it.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

ACHV: Achieve's Busy Day
ACHV: Achieve's Busy Day

Yahoo

time8 minutes ago

  • Yahoo

ACHV: Achieve's Busy Day

By John Vandermosten, CFA NASDAQ:ACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted a flurry of press releases last week announcing the submission of its new drug application (NDA), a partnership with Omnicom for cytisinicline commercialization, a proposed public offering and the pricing of the offering. The capital raise was closed on June 30th. This is the culmination of more than a decade of work developing cytisinicline for smoking cessation. Now that the development phase of cytisinicline for smoking cessation is coming to a close, we look towards the regulatory and commercialization phases. We expect to see the FDA formally accept the NDA by late August and Achieve's management team to turn its attention towards the sales effort. Assuming normal turnaround times, we expect the FDA to set a target action date sometime in 2Q:26. NDA Submission Achieve announced its NDA submission of cytisinicline for smoking cessation in a June 26th press release. The company conducted two Phase III studies, an open label safety study and other studies that evaluated over 2,000 participants with the results demonstrating the safety, efficacy and tolerability of cytisinicline. We expect to see acceptance of the NDA within 60 days and further expect additional safety data from the ongoing ORCA-OL trial to be shared with the agency near year end. Commercialization Partnership Now that the new drug application has been submitted, Achieve is further advancing its commercialization efforts. During its earnings calls, the company has outlined its commercialization strategy and is now partnering with Omnicom Group to execute the plan. Omnicom Group provides brand and advertising services to thousands of clients globally and is one of the world's largest advertising and marketing services companies. Achieve will work with Omnicom subsidiary Credera, which is focused on digital transformation services. Credera combines consulting, artificial intelligence (AI) and technology expertise to build consumer technology platforms, integrate marketing technology systems and provide strategic consulting services. It will help Achieve to precisely target and engage healthcare professionals and patients through optimization of channel performance and acceleration of meaningful engagement. The team executing the initiative will include Goodby, Silverstein & Partners, DDB Health, and Ketchum Health which are health care-focused subsidiaries of the Omnicom marketing group. The various subsidiaries will provide expertise in consumer brand development, medical education and strategic public relations and communications, applying industry insights to support cytisinicline launch. In the Achieve partnership, Ketchum Health brings public relations and communications expertise, while Credera handles technology, Goodby Silverstein provides creative advertising, and DDB Health focuses on healthcare marketing. The partnership will use generative AI, predictive analytics and social listening to enhance targeting and personalization. Using a comprehensive approach, it will also employ healthcare applications, pharmacies and data providers to expand the reach and depth of insights. Omnicom has worked as media agency, digital and brand experience for other pharmaceutical and biotechnology clients including established firms such as AbbVie, AstraZeneca, Novartis and Moderna among others. Achieve will be the first small company that Omnicom has supported in commercializing a newly approved drug. Therefore, Omnicom will take on a broader strategic role than in its past partnerships. The Omnicom team will help communicate the optimal message to the provider and patient and monitor its effectiveness in real time. This will allow for rapid course corrections and focus on high value activities. Achieve has identified several target groups for its marketing efforts that are stratified by age, social media use and other demographic data. It was able to identify these groups based on subject experiences in the company's many clinical trials. We anticipate that the structure of Achieve's internal marketing team will be heavily tilted toward supporting the digital campaign with contract representatives available for in-person physician meetings when appropriate. Public Offering On June 30th, 2025 Achieve closed its $45 million capital raise. 15 million shares were issued at $3.00, each of which included an attached warrant exercisable at $3.00 per share. An additional 1,766,666 warrants were issued upon the partial exercise by the underwriters of their option to purchase additional shares, bringing total issued warrants to approximately 16.8 million. Net proceeds from the capital raise are estimated to be $41.3 million as disclosed in the June 27th Form 8-K filing. ORCA-OL Safety Trial Achieve began 2025 by announcing that 300 participants had completed six months of treatment in the Ongoing Research of Cytisinicline for Addiction Program, Open Label (ORCA-OL) trial. The Data Safety Monitoring Committee (DSMC) identified no safety concerns as of this milestone allowing registrational filing with the FDA. As of May 2025, a third DSMC safety review was completed which also found no unexpected treatment-related adverse events. As of the first quarter reporting date, more than 100 subjects had completed one year of cytisinicline treatment. Furthermore, about 75% of the 479 (~360) individuals remained on treatment in the trial. We think that it is a material real-world positive that so many participants would remain on a smoking cessation product for that long a period suggesting that cytisinicline is well tolerated. This is particularly notable given the high discontinuation rates for Chantix and the associated unpleasant side effects such as nausea, headache, abnormal dreams and constipation.[1] Achieve expects to complete the one-year safety data package in the next few months and will submit this to the FDA by the 120-day safety review milestone. This should be around year-end 2025. Achieve expects that it will far exceed the 100-patient minimum required for one year of safety observations and could see as many as 300 patients with one year of exposure. Since one of the secondary endpoints is efficacy, this study should be able to show a wealth of data that can help providers use cytisinicline more effectively especially in chronic areas of disease such as Chronic Obstructive Pulmonary Disease (COPD) and cardiology. Milestones Development of cytisinicline product label for smoking cessation – 1H:25 Completion of six months of ORCA-OL safety data for 300 subjects – January 2025 Attendance at Oppenheimer Healthcare Life Sciences Conference, Virtual – February 2025 Attendance at Barclays Healthcare Conference, Miami – March 2025 Selection of 3rd party logistics partner – 2Q:25 NDA Submission – 2Q:25 FDA data submission from patients with twelve months of exposure to cytisinicline – 4Q:25 Launch of Phase III vaping trial – 1H:26 FDA target action date for cytisinicline NDA – 1H:26 Launch of cytisinicline – 3Q:26 SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our for additional information on Zacks SCR. DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives quarterly payments totaling a maximum fee of up to $40,000 annually for these services provided to or regarding the issuer. Full Disclaimer . ________________________ [1] Minian, N., et al. Identifying determinants of varenicline adherence using the Theoretical Domains framework: a rapid review. BMC Public Health. March 2024.

How China is leading the humanoid robots race
How China is leading the humanoid robots race

Yahoo

time14 minutes ago

  • Yahoo

How China is leading the humanoid robots race

I've worked at the bleeding edge of robotics innovation in the United States for almost my entire professional life. Never before have I seen another country advance so quickly. Psychologists now know exactly what makes someone cool. Turns out, the definitions are universal 3% mortgage rates aren't dead—housing market sees 127% increase in buyers taking over old loans There's a reason your Sam's Club rotisserie chicken looks different In the span of the last few years, China has overtaken the U.S. as the leader in the robotics race, especially when it comes to humanoid robots designed to mimic the human body and behavior. Earlier this year China literally raced robots against human counterparts, and they show no sign of slowing down. While AI steals the investment and media spotlight, the competition for humanoid robotics supremacy has been quietly accelerating for 50 years, and we're now on the cusp of a momentous breakthrough. Mass-produced humanoid robots may reach us within the next 3–5 years, and the market is predicted to grow to $38B within just 10 years. China is poised to capture the lion's share of this industry: Morgan Stanley found that 56% of robotics companies are already based there. However, this competition isn't just about market share—it's about industrial supremacy. Fixed industrial robots now operate with productivity rates estimated to be 10 times that of humans, working almost 24/7 with virtually no errors. In this new era of free-moving humanoid robots, adaptable machines will navigate entire factory floors with equal precision and even higher productivity rates than their fixed (and human) counterparts. American companies like Boston Dynamics are building impressive prototypes but those don't win industrial wars, production does. If the U.S. continues to lag behind in the robotics race, American businesses will face increased supply chain dependence on China and citizens could see wage stagnation and job losses to robotics leaders overseas. I witnessed the U.S. lead the world in robotic advancements. Two of my humanoid robots went into space; one called 'Robonaut' now lives in the Smithsonian. Over the past decade, our momentum has slowed. To take back robotics supremacy, the U.S. must overcome four critical hurdles that could cost us this race. Yes, Chinese robotics startups are benefiting from established supply chains, local adoption opportunities, and strong national government support, but nagging domestic problems are holding the United States back, regardless of any other country's advancements. First, we're battling our own cultural fears. There's a prevailing anxiety that robots will replace human jobs, particularly in factories. While massive change in manufacturing is fast approaching, the fear of replacement is not only wrong—it's counterproductive. Humanoid robots excel at 'dirty, dark, and dangerous' jobs that often lack willing human labor anyway. To overcome U.S. cultural fears around robotics, we must think of robots not as standing in our place but standing by our sides. WWII was won as much on the mechanized manufacturing floor as on the battlefield and novel machines were essential to winning the space race. When Robonaut shook hands with a fellow astronaut aboard the International Space Station, it was proof that robots can and should support human work, not compete with it. Second, we're not cultivating the people behind the humanoids. The real challenge in winning the humanoid race isn't job displacement; it's the massive lack of skilled domestic workers to develop, operate, and maintain advanced robotics. At Texas A&M, I teach brilliant students ready to tackle real-world problems with robots. Educating the workforce about how to leverage robots will empower the next generation and dispel fear. However, across the country, preparation for careers in STEM is lacking. We need more accessible science programs, apprenticeships, and pathways into robotics now. Third, the economics still intimidate us. Developing humanoid robots involves significant upfront costs and still faces expensive technical hurdles, including improving spatial awareness and task adaptability. But here's what the bean counters are missing: once mass production kicks in, the cost of robot labor could plummet from $10 to just $0.25 per hour in as little as 10 years. The industry will transform overnight and whichever country controls this shift owns the future of manufacturing. Focusing on the future affordability of robot labor will incentivize both the private and public sector to invest now. Fourth, our policy framework is falling behind. While the U.S. offers some incentives for research and innovation, they pale in comparison to China's commitment. The Chinese government has poured over $20 billion into robotics and next-generation technologies, providing subsidies for startups and covering costs for equipment and talent acquisition. They're projected to match U.S. robotics research and development levels by 2034. Meanwhile, current U.S. tax code continues to disincentivize longer-term innovation projects by forcing companies to pay more up front for R&D. As the U.S. federal government increasingly overlaps its ambitions with AI tech companies, so too must it champion the development of humanoid robots as a national security and productivity imperative. In tandem with overcoming these inherent challenges, the U.S. must seize two unique opportunities that offer a high return on investment and a clear path to victory. Humanoid robots can maintain our edge in advanced manufacturing. Humanoids integrated with AI and embedded into the internet of things will create smart factories that enhance precision, improve product quality, and accelerate production times. The U.S. currently leads the world in the development of smart textiles—humanoid robots could accelerate production to maintain this advantage. Warehouses offer an arena for rapid humanoid adoption. The number of warehouses across the U.S. continues to expand, with Amazon recently announcing plans for dozens more across rural areas. Our vast network of warehouses is primed for humanoid robots to revolutionize its operations by automating sorting, packing, and transport alongside humans to boost efficiency and slash costs. These aren't theoretical applications: they're already being tested at sites like BMW's South Carolina plant, where robotics partners are deployed for logistics and warehousing tasks. These deployments leverage our existing strengths in technology and innovation while addressing real, immediate market needs. We don't need to wait for the perfect humanoid robot—we can start dominating these sectors today and build from there. This race not just about machines; it's about maintaining U.S. leadership in technology, safety, and industrial strength. If we want the next generation of robotics to serve American interests, we must act now or be left standing on the sidelines of the next industrial revolution. During my two decades at NASA, I saw what American innovators can achieve when given a mission. We sent robots to the Moon, Mars, and into orbit—not because it was easy, but because we believed it mattered for future generations. That same spirit must drive our investment in humanoid robotics today so we can cross the finish line first tomorrow. This post originally appeared at to get the Fast Company newsletter:

Colorado Medicaid recipient fears losing coverage after "big, beautiful bill" passes
Colorado Medicaid recipient fears losing coverage after "big, beautiful bill" passes

CBS News

time21 minutes ago

  • CBS News

Colorado Medicaid recipient fears losing coverage after "big, beautiful bill" passes

Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been Colorado Medicaid recipient concerned about losing coverage now that "big, beautiful bill" has been President Trump signed what he called the "One Big Beautiful Bill Act" during a celebratory event on July 4 after the bill narrowly passed the House on Thursday, with Colorado's congressional delegation voting along party lines. The legislation makes a number of changes to domestic policies, including permanently increasing the child tax credit to $2,200, allowing tipped workers to deduct tips and overtime from federal taxes, and boosting funding for U.S. Immigration and Customs Enforcement. It also eliminates tax incentives for clean energy, electric vehicles, and energy efficiency programs. In addition, the bill includes stronger restrictions on Medicaid, which provides health care coverage to over 70 million low-income and disabled Americans, according to data from the U.S. Department of Health and Human Services. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection left her unable to work, said she's worried about the changes. "It scares me, not only for myself, but for all of the people who are on Medicaid, who are just trying to survive," she said. Lindsey Schoen, a Colorado resident who got on Medicaid in 2014 after a severe bacterial infection, talks to CBS News Colorado via Zoom about concerns she has about possible cuts to Medicaid after President Trump signed the "One Big Beautiful Bill Act" on July, 4, 2025. CBS Schoen said the coverage helped her regain her health and return to work. "Because of Medicaid, I've been able to get well enough to actually work again," Schoen said. "I work for the State of Colorado, for the Division of Youth Services, and I love my job so much." One in four Coloradans receives Medicaid benefits -- about 1.72 million people, according to the Colorado Department of Health Care Policy and Financing. Annie Lee, president and CEO of Colorado Access, which helps administer Medicaid in the state, said the new bill could have a sweeping effect. "What this bill does is really shift the financial burden to states," Lee said. "The majority of the things in the bill that was just passed are set to take effect next year or the following year. There's kind of a graduated impact for most of the things in the bill." Stretchers for an operating room are seen at Denver Health in Denver, Colorado on Thursday, April 25, 2024. Hyoung Chang/The Denver Post via Getty Images The legislation adds work requirements for certain adults to keep receiving Medicaid benefits. Supporters argue it will motivate able-bodied adults to improve their lives. But Schoen said many Medicaid recipients already work. "A lot of us do work. We try really hard. We don't just lie around on the couch all day," she said. "I was hospitalized seven times last year, and I had two surgeries, and I worked the entire time. But there are many times where it just feels like I'm walking on thin ice. If one more thing happens, the whole house of cards could just collapse." Lee warned the bill is anticipated to result in "large-scale loss of health insurance coverage for Coloradans." Schoen echoed that concern. "I just feel like the people who we've elected to be our proxies have just turned around and pushed us off a cliff," she said. "And there's no safety net down there."

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store